Treatment of Meningitis in HIV-Positive Patients
For HIV-associated cryptococcal meningitis, treat with amphotericin B deoxycholate (0.7-1.0 mg/kg/day IV) plus flucytosine (100 mg/kg/day orally in 4 divided doses) for 2 weeks, followed by fluconazole 400 mg daily for 8 weeks, then fluconazole 200 mg daily for at least 1 year. 1
Cryptococcal Meningitis: The Primary Concern
Cryptococcal meningitis is the most common and deadly meningitis in HIV-positive patients with advanced immunosuppression (CD4 <100 cells/μL). This is the focus of evidence-based treatment guidelines.
Induction Therapy (First 2 Weeks)
Preferred regimen:
- Amphotericin B deoxycholate 0.7-1.0 mg/kg/day IV PLUS flucytosine 100 mg/kg/day orally for 2 weeks (A-I evidence) 1
- This combination achieves the most rapid fungal clearance and lowest mortality
Alternative if renal dysfunction present:
- Liposomal amphotericin B (3-4 mg/kg/day IV) or amphotericin B lipid complex (5 mg/kg/day IV) plus flucytosine for 2 weeks (B-II evidence) 1
Shortened regimen with equivalent outcomes:
- Recent evidence shows 1 week of amphotericin B deoxycholate plus flucytosine followed by fluconazole on days 8-14 has lower 10-week mortality (24.8%) compared to standard 2-week regimens, with significantly fewer adverse events 2, 3
- This shortened regimen reduces grade 3-4 anemia risk by 69% compared to 2-week amphotericin courses 3
Resource-limited settings without amphotericin access:
- Fluconazole 1200 mg/day plus flucytosine 100 mg/kg/day for 2 weeks (B-II evidence) 1, 4
- This all-oral regimen shows 35% 10-week mortality versus 70% with fluconazole monotherapy 4
- Never use fluconazole monotherapy for induction - mortality approaches 70% 4
Consolidation Therapy (Weeks 3-10)
- Fluconazole 400 mg daily for 8 weeks (A-I evidence) 1
Maintenance Therapy (Secondary Prophylaxis)
- Fluconazole 200 mg daily for at least 1 year (A-I evidence) 1
- Can discontinue only after: CD4 >100 cells/μL for ≥3 months, undetectable viral load, and minimum 1 year of antifungal therapy 1
Critical Management Principles
Intracranial Pressure Management
Aggressively manage elevated intracranial pressure - this is a major determinant of mortality 1:
- Perform daily lumbar punctures if opening pressure >25 cm H₂O
- Remove sufficient CSF to reduce opening pressure by 50% or to <20 cm H₂O
- Repeat as needed based on symptoms
- Do not use corticosteroids for elevated ICP in cryptococcal meningitis
Antiretroviral Therapy Timing
- Delay ART initiation for 2-10 weeks after starting antifungal therapy 1
- Earlier ART initiation increases risk of immune reconstitution inflammatory syndrome (IRIS)
- IRIS can present as paradoxical worsening despite negative CSF cultures 1, 5
Monitoring for Treatment Failure vs IRIS
Distinguish between:
- Treatment failure: Persistent positive CSF cultures, consider drug resistance or compliance issues
- IRIS: Worsening symptoms with negative cultures after immune recovery, may require immunosuppression with corticosteroids plus steroid-sparing agents like mycophenolate mofetil for refractory cases 5
Tuberculous Meningitis in HIV
For TB meningitis in HIV-positive patients:
- Standard 4-drug anti-tuberculosis therapy for 12 months
- Do NOT use adjunctive dexamethasone - a large randomized trial showed no mortality benefit in HIV-positive adults (44.1% mortality with dexamethasone vs 49.0% with placebo, not statistically significant) 6
- This contrasts with HIV-negative TB meningitis where steroids may be beneficial
Common Pitfalls to Avoid
- Never use fluconazole monotherapy for induction - mortality is unacceptably high at 70% 4
- Do not use corticosteroids for cryptococcal meningitis - no proven benefit and may worsen outcomes 1
- Do not start ART immediately - wait 2-10 weeks to reduce IRIS risk 1
- Do not neglect intracranial pressure management - daily therapeutic lumbar punctures save lives 1
- Ensure flucytosine is included when available - combination therapy with amphotericin reduces mortality by 34% compared to amphotericin alone 3